New pill shows promise in slowing lung scarring disease

NCT ID NCT06331624

Completed Disease control Sponsor: GRI Bio Operations, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an oral drug called GRI-0621 in 35 adults with idiopathic pulmonary fibrosis (IPF), a chronic lung disease that causes scarring and breathing difficulty. Participants took either the drug or a placebo daily for 12 weeks. The main goals were to check safety and measure changes in blood markers of lung scarring. The drug aims to calm a specific immune cell (NKT1) thought to drive fibrosis, but it is not a cure—patients would still need ongoing management.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDIOPATHIC PULMONARY FIBROSIS IPF

Contacts and locations

Locations

Concord General Repatriation Hospital

Concord, New South Wales, 2139, Australia
MUSC Pulmonary Research

Charleston, South Carolina, 29425, United States
Mayo Clinic

Jacksonville, Florida, 32224, United States
Montefiore Medical Center

The Bronx, New York, 10467, United States
Newport Native MD, Inc.

Newport Beach, California, 92663, United States
Norfolk & Norwich University Hospital

Norwich, Norwich, United Kingdom
Oxford University Hospitals NHS Foundation Trust

Oxford, OX3 7LE, United Kingdom
Royal Devon and University Healthcare NHS Foundation Trust

Exeter, EX2 5DW, United Kingdom
Royal Infirmary Edinburgh

Edinburgh, Scotland, EH16 4SA, United Kingdom
Royal Papworth Hospital NHS Foundation Trust

Cambridge, CB2 0BB, United Kingdom
Southeastern Research Center

Winston-Salem, North Carolina, 27103, United States
St. George Hospital

Kogarah, New South Wales, 2217, Australia
The Canberra Hospital

Garran, Australian Capital Territory, 2605, Australia
University College London Hospitals

London, London, United Kingdom
University Hospital Birmingham, Queen Elizabeth Hospital

Birmingham, B15 2GW, United Kingdom
Western Health and Social Care Trust (WHSCT)

Londonderry, BT47 6SB, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.